Expand SNTI Menu
SNTI MENU

SNTI Latest Press Releases

-- December 9, 2025 --

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia Globe Newswire 7:00 AM
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile Globe Newswire 7:00 AM

-- December 4, 2025 --

Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET Globe Newswire 8:45 AM

-- November 13, 2025 --

Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December Globe Newswire 4:30 PM

-- November 3, 2025 --

Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025 Globe Newswire 9:05 AM

-- October 16, 2025 --

Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference Globe Newswire 9:05 AM

-- October 6, 2025 --

Senti Bio to Present at BioJapan Globe Newswire 9:05 AM

-- September 18, 2025 --

Senti Bio to Present at the MedInvest Biotech & Pharma Conference Globe Newswire 9:15 AM

-- September 2, 2025 --

Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference Globe Newswire 9:05 AM

-- August 15, 2025 --

JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025 ACCESS Newswire 10:00 AM

-- August 14, 2025 --

Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech Globe Newswire 9:15 AM

-- August 12, 2025 --

Senti Bio Participates in Virtual Investor "What This Means" Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia Globe Newswire 9:15 AM

-- August 5, 2025 --

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia Globe Newswire 8:30 AM

-- July 22, 2025 --

Senti Biosciences Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Globe Newswire 8:45 AM
JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live ACCESS Newswire 8:40 AM

-- July 21, 2025 --

Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum Globe Newswire 8:55 AM

-- July 18, 2025 --

JTC Team Announces Participating Line Up for the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference ACCESS Newswire 11:00 AM
Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors Globe Newswire 8:55 AM
Market Data Delayed 15 Minutes